Abbisko presentation at ACoP 2024: 

Abstract Number: M-082

Title: Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for pimicotinib

Poster Time: 11 Nov, 2024

About Pimicotinib

Pimicotinib is a novel, orally available, highly selective, and highly potent small molecule inhibitor of CSF-1R independently discovered and developed by Abbisko Therapeutics. It has obtained the Breakthrough Therapy Designation (BTD) from China NMPA and the U.S. FDA, as well as the PRIME designation from EMA. Furthermore, the U.S. FDA granted Fast Track Designation (FTD), and Orphan Drug Designation (ODD) granted by EMA, for the treatment of TGCT patients who are not amenable to surgery.

Abbisko is conducting "a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of pimicotinib (ABSK021) in patients with tenosynovial giant cell tumor (protocol No.: ABSK021-301)."